What is the likely cause of new diffuse, leg‑predominant pain in a 44‑year‑old woman with a history of breast cancer treated with chemotherapy and radiotherapy seven years ago, after a resolved chemotherapy‑induced neuropathy, given normal inflammatory markers, normal white blood cell count, and no fever?

Likely Cause: Recurrent Chemotherapy-Induced Peripheral Neuropathy (CIPN)

The most likely cause is recurrent or late-onset chemotherapy-induced peripheral neuropathy (CIPN) from her prior taxane or platinum-based chemotherapy, which can persist or recur years after treatment completion, particularly affecting the lower extremities in a length-dependent pattern.

Clinical Reasoning

Why CIPN is the Primary Diagnosis

The clinical presentation strongly suggests CIPN based on several key features:

• Timing: CIPN can persist or worsen years after chemotherapy completion 1, 2. Notably, symptoms can follow a "coasting phenomenon" where neuropathy worsens for 2-3 months after treatment cessation, particularly with oxaliplatin 2

• Distribution pattern: Her leg-predominant pain fits the classic "glove and stocking" distribution of CIPN, which is symmetric, distal, and length-dependent 1. The lower extremities are typically more severely affected than upper extremities, especially with paclitaxel 2

• Migratory nature: The varying locations in her legs at different times is consistent with sensory neuropathy, where symptoms can fluctuate in intensity and location 1

• Previous resolution then recurrence: The fact that her neuropathy initially cleared but has now returned is well-documented. Studies show that 27-58% of breast cancer survivors report long-term CIPN symptoms years after treatment 3, 4, 5

Supporting Evidence from Breast Cancer Survivors

Research specifically in breast cancer survivors demonstrates:

• High prevalence: 38-58% of patients treated with taxanes report persistent CIPN symptoms years later 3, 4
• Paclitaxel vs. docetaxel: If she received paclitaxel, her risk is particularly high—44% report long-term symptoms compared to 31% with docetaxel 3
• Pain characteristics: 30-53% of those with CIPN experience painful neuropathy 6, 5

Why Other Diagnoses are Less Likely

The normal inflammatory markers, normal white count, and absence of fever effectively rule out:

• Inflammatory neuropathies (would show elevated ESR/CRP)
• Infectious causes (would show fever, elevated WBC)
• Vasculitis (would show inflammatory markers)
• Acute inflammatory demyelinating polyneuropathy

Cancer recurrence must be considered but is less likely given:

• Seven years disease-free (excellent prognosis)
• No systemic symptoms
• Normal inflammatory markers

However, metastatic disease to bone or nerve involvement should still be excluded with appropriate imaging if clinical suspicion warrants.

Diagnostic Approach

Essential Next Steps

1. Detailed chemotherapy history: Identify specific agents (taxanes, platinum compounds, vinca alkaloids), cumulative doses, and treatment duration 1, 2

2. Focused neurological examination: Look for:

   • Reduced vibration sense in toes (earliest sign)
   • Decreased ankle reflexes
   • Stocking distribution sensory loss
   • Preserved motor function (CIPN is predominantly sensory) 1

3. Exclude other causes:

   • Diabetes screening (HbA1c)
   • Thyroid function (TSH)
   • Vitamin B12 level
   • Consider imaging if atypical features suggest recurrence

4. Nerve conduction studies: Only if diagnosis unclear or atypical features present—not routinely needed 2

Management Recommendations

First-Line Treatment

Duloxetine 30 mg daily for 1 week, then increase to 60 mg daily 1, 7

This is the only agent with moderate-level evidence for treating CIPN. The initial lower dose reduces nausea risk, with expected 30-50% pain reduction 7.

Second-Line Options (if duloxetine fails or is not tolerated)

Based on evidence from other neuropathic pain conditions 1:

• Gabapentin (start 300 mg at bedtime, titrate to 900-3600 mg/day divided TID)
• Tricyclic antidepressants like nortriptyline (start 10-25 mg at bedtime, titrate to 50-150 mg)
• Topical compound gel (baclofen/amitriptyline/ketamine)

Non-Pharmacological Interventions

Physical activity/exercise has demonstrated benefit in multiple RCTs 7 and should be recommended regardless of pharmacological treatment.

Acupuncture may be offered, though evidence specifically for CIPN is limited compared to other pain syndromes 7.

Critical Pitfalls to Avoid

1. Do not prescribe acetyl-L-carnitine: It is associated with worse CIPN symptoms and carries a Grade H (harm) recommendation 8

2. Do not delay cancer surveillance: While CIPN is most likely, ensure she remains current with mammography and clinical breast exams to exclude recurrence

3. Assess fall risk: CIPN significantly increases fall risk (42% in moderate-to-severe cases) 4. Address home safety and consider physical therapy referral

4. Screen for psychological distress: CIPN is associated with increased anxiety, depression, and insomnia 4. These comorbidities worsen quality of life and require concurrent management

5. Consider obesity as risk factor: If BMI ≥30 kg/m², this independently increases CIPN risk (OR 2.13) 9, 4 and should be addressed

Quality of Life Impact

CIPN in the lower extremities causes more intense pain and greater daily life interference than surgical site pain, despite being less common 5. This underscores the importance of aggressive symptom management to preserve function and quality of life in this 44-year-old survivor.